Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies Holdings, Inc. reported that the U.S. District Court for the District of Massachusetts has preliminarily approved a global settlement of multiple stockholder derivative matters brought on the Company’s behalf. The settlement, documented in an August 5, 2026 stipulation, covers the consolidated federal derivative action, two related Delaware Court of Chancery derivative actions, and a stockholder litigation demand.
The settlement provides for a package of corporate governance reforms, including amendments to the Audit Committee Charter, Marketing Policy, Disclosure Committee Charter, and Corporate Governance Guidelines, creation of a management-level compliance committee, and enhanced roles for the General Counsel in legal and compliance oversight. These reforms will be implemented within 30 days of the settlement’s effective date and maintained for five years. The settlement does not require any payment by Evolv; plaintiffs’ attorneys’ fees and expenses of $1,275,000 are to be paid by the Company’s insurers. A settlement hearing is scheduled for October 21, 2026, and current stockholders as of August 5, 2026 may object or be heard subject to specified procedures.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 13,440,609 shares of EVOLV TECHNOLOGIES HOLDINGS INC Class A stock. This represents 7.5% of the class. BlackRock reports sole voting power over 13,159,037 shares and sole dispositive power over 13,440,609 shares, with no shared voting or dispositive power.
BlackRock notes that various underlying clients and investors have economic rights to dividends and sale proceeds, but no single such person has more than five percent of the outstanding common shares.
Michael Ellenbogen, a director of Evolv Technologies Holdings, Inc., exercised stock options for 80,745 shares of Class A Common Stock at $0.24 per share and on the same date sold 80,745 shares at a weighted-average price of $5.94 under a Rule 10b5-1 trading plan. Following these transactions, he holds 2,083,961 shares directly, 151,135 shares indirectly through the Family Horizon Trust, and 897,014 stock options expiring on September 13, 2027.
Evolv Technologies Holdings, Inc. had its warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, stating that the exchange and the issuer complied with 17 CFR 240.12d2-2(b) and 12d2-2(c).
Evolv Technologies Holdings, Inc. reported results of its annual stockholder meeting held on June 18, 2026. A total of 138,936,379 shares of Class A common stock were represented, equal to approximately 77.35% of shares outstanding as of the April 24, 2026 record date.
Stockholders elected Class II directors Neil Glat and Richard Shapiro to serve until the 2029 annual meeting. They also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.
Evolv Technologies Holdings director David Mounts Gonzales exercised restricted stock units that vested on June 17, 2026, converting them into 27,050 shares of Class A common stock. These RSUs represented a right to receive one share each and carried no expiration date.
After this compensation-related conversion, Gonzales directly holds 201,789 shares of Evolv Class A common stock. The filing does not show any open-market purchases or sales, only the exercise of equity awards previously granted to him.
Evolv Technologies Holdings, Inc. director Mark J. Sullivan exercised restricted stock units into common shares. On June 17, 2026, 27,050 RSUs vested in full and were converted into 27,050 shares of Class A common stock at no exercise price. Following this equity award vesting and conversion, he holds 242,628 Class A shares directly, with no same-day sale reported.
Evolv Technologies Holdings director Henrik Kuhl reported routine equity compensation activity. On June 18, 2026, he received a grant of 28,318 Restricted Stock Units, each representing one share of Class A common stock. These RSUs vest in full at the earlier of June 18, 2027 or the day immediately before the next annual meeting.
On June 17, 2026, 9,291 RSUs vested in full and were exercised into 9,291 shares of Class A common stock at no cash exercise price. Following these transactions, he directly holds 9,291 shares of Class A common stock from this exercise, along with the new 28,318-unit RSU award subject to future vesting.
Evolv Technologies Holdings director Kevin M. Charlton reported equity compensation and related share activity. He received a grant of 28,318 Restricted Stock Units (RSUs) on Class A common stock that will vest in full at the earlier of June 18, 2027 or the day immediately before the company’s next annual meeting. On June 17, 2026, a prior award of 27,050 RSUs vested in full, and these units were converted into the same number of Class A common shares, increasing his direct holdings to 359,010 shares. He also reports 44,081 Class A common shares held indirectly through an IRA.
Evolv Technologies Holdings director Richard A. Shapiro reported equity compensation activity in the form of restricted stock units (RSUs) and common stock. He received a grant of 28,318 RSUs, each representing a contingent right to one share of Class A common stock. These RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the company’s next annual meeting date.
Separately, 27,050 RSUs vested in full on June 17, 2026 and were exercised into 27,050 shares of Class A common stock, after which he held 79,565 shares directly. The filing also shows indirect holdings of 16,400 shares held by his spouse in a retirement plan, 22,500 shares held by a trust for which he has voting and dispositive power over the share-based assets, and 30,000 shares held by his spouse.